Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.92 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.79 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.79 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18175266 | 1.00 | DPP4 (0.92) | DPP4DPP8DPP9PIK3CAPREP | |
| SCHEMBL13882110 | 1.00 | DPP4 (0.92) | DPP4DPP8DPP9PIK3CAPREP | |
| SCHEMBL13287073 | 1.00 | DPP4 (0.92) | DPP4DPP8DPP9PIK3CAPREP | |
| SCHEMBL1040802 | 0.96 | DPP4 (1.00) | DPP4DPP8DPP9PIK3CAPREP | |
| SCHEMBL2555136 | 0.96 | DPP4 (1.00) | DPP4DPP8DPP9PIK3CAPREP | |
| SCHEMBL646974 | 0.96 | DPP4 (1.00) | DPP4DPP8DPP9PIK3CAPREP | |
| SCHEMBL163502 | 0.96 | DPP4 (1.00) | DPP4DPP8DPP9PIK3CAPREP | |
| SCHEMBL20162036 | 0.96 | DPP4 (1.00) | DPP4DPP8DPP9PIK3CAPREP | |
| SCHEMBL8021363 | 0.94 | DPP4 (0.81) | DPP4DPP8DPP9PIK3CAPREP | |
| SCHEMBL14641775 | 0.94 | DPP4 (0.81) | DPP4DPP8DPP9PIK3CAPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582709-B1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI SA (FR) | 2018-01-24 | — | — | EP | disclosed |
| EP-2897939-B1 | BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES FOR TREATING METABOLIC OR CARDIOVASCULAR DISEASES | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| EP-2203415-B1 | (CYCLOPROPYL-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINES | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| EP-2847191-B1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-06-15 | — | — | EP | disclosed |
| EP-2766349-B1 | OXATHIAZINE DERIVATIVES SUBSTITUTED WITH CARBOCYCLES OR HETEROCYCLES, METHOD FOR PRODUCING SAME, DRUGS CONTAINING SAID COMPOUNDS, AND USE THEREOF | SANOFI SA (FR) | 2016-06-01 | — | — | EP | disclosed |
| EP-2771340-B1 | 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-04-13 | — | — | EP | disclosed |
| EP-2760862-B1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2015-10-21 | — | — | EP | disclosed |
| US-9156796-B2 | Benzoimidazole-carboxylic acid amide derivatives as APJ receptor modulators | SANOFI (FR) | 2015-10-13 | — | — | US | disclosed |
| US-9156796-B2 | Benzoimidazole-carboxylic acid amide derivatives as APJ receptor modulators | SANOFI (FR) | 2015-10-13 | — | — | US | disclosed |
| US-9133181-B2 | Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-7759366-B2 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| WO-2010003624-A2 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009149819-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
| US-20090298871-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | US | disclosed |
| US-20090298871-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | US | disclosed |
| US-20090264402-A1 | NOVEL DIPHENYLAZETIDINONE SUBSTITUTED BY PIPERAZINE-1-SULFONIC ACID AND HAVING IMPROVED PHARMACOLOGICAL PROPERTIES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090203578-A1 | CERTAIN CRYSTALLINE DIPHENYLAZETIDINONE HYDRATES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090203578-A1 | CERTAIN CRYSTALLINE DIPHENYLAZETIDINONE HYDRATES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | GPR119, GIPR, LIPC | DPP4 27/4885DPP8 88/4885DPP9 89/4885 |
| US-20090298871-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | PPARD, PPARG, PPARA | DPP4 160/4885DPP8 742/4885DPP9 606/4885 |
| US-20090203578-A1 | CERTAIN CRYSTALLINE DIPHENYLAZETIDINONE HYDRATES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR USE | CYP46A1, CYP2F1, LIPA | DPP4 150/4885DPP8 144/4885DPP9 191/4885 |
| US-20090264402-A1 | NOVEL DIPHENYLAZETIDINONE SUBSTITUTED BY PIPERAZINE-1-SULFONIC ACID AND HAVING IMPROVED PHARMACOLOGICAL PROPERTIES | DPP7, SCN5A, DCTN1 | DPP4 40/4885DPP8 142/4885DPP9 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.